Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification

Diabetes Research and Clinical Practice

Volumn 123, Issue , 2017, Pages 209-217

  Khunti, Kamlesh ^a   Damci, Taner ^b   Husemoen, Lise Lotte ^c   Babu, Vinay ^c   Liebl, Andreas ^d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NOVO NORDISK A S   (Denmark)

^d Fachklinik Bad Heilbrunn   (Germany)

Author keywords

Basal insulin detemir; HbA1c; Hypoglycemia; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN DETEMIR; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERSONALIZED MEDICINE; POST HOC ANALYSIS; TREATMENT DURATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85007545241     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.11.028     Document Type: Article

References (23)

1. [1] AACE/ACE comprehensive diabetes management algorithm. Endocr Pract, 21(4), 2015.
2. [2] American Diabetes Association, Standard of Medical Care in Diabetes–2016. Diabetes Care, 39, 2016, S1.
3. [3] National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NG28. December 2015.
4. [4] Khunti, K., Wolden, M.L., Thorsted, B.L., et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36 (2013), 3411–3417.
5. [5] Gerstein, H.C., Miller, M.E., Genuth, S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
6. [6] Holman, R.R., Farmer, A.J., Melanie, M.J., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:18 (2009), 1736–1747.
7. [7] Peyrot, M., Rubin, R.R., Lauritzen, T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005), 2673–2679.
8. [8] Stargardt, T., Gonder-Frederick, L., Krobot, K.J., et al. Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health Qual Life Outcomes, 7, 2009, 91.
9. [9] Peyrot, M., Rubin, R.R., Khunti, K., Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 4:Suppl. 1 (2010), S11–S18.
10. TM study. Diabetes Obes Metab 11 (2009), 623–631.
11. [11] Khunti, K., Caputo, S., Damci, T., et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab 14 (2012), 1129–1136.
12. [12] Khunti, K., Nikolajsen, A., Thorsted, B.L., et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab 18 (2016), 401–409.
13. [13] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
14. [14] Balkau, B., Francois, C.G., Freemantle, N., et al. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study. Diabetes Res Clin Prac 108 (2015), 432–440.
15. [15] Home, P.D., Shen, C., Hasan, M.I., et al. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care 37 (2014), 1237–1245.
16. [16] Riddle, M.C., Vlajnic, A., Zhou, R., et al. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulinglargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 15:9 (2013), 819–825.
17. [17] Rosenstock, J., Davies, M., Home, P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 51 (2008), 408–416.
18. [18] Philis-Tsimikas, A., Charpentier, G., Clauson, P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28 (2006), 1569–1581.
19. [19] DCCT, Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 24 (2001), 1711–1721.
20. [20] UKPDS, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
21. [21] Russell-Jones, D., Danne, T., Hermansen, K., et al. Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?. Diabetes Obes Metab 17 (2015), 919–927.
22. [22] Brod, M., Pfeiffer, K.M., Barnett, A.H., et al. Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom. Curr Med Res Opin 7 (2016), 1–9.
23. [23] Zafar, A., Stone, M.A., Davies, M.J., et al. Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. Diabet Med 32 (2015), 407–413.